TransMedics Group (NASDAQ:TMDX) Stock Rating Lowered by Zacks Research

TransMedics Group (NASDAQ:TMDX) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research firms also recently issued reports on TMDX. Piper Sandler decreased their price objective on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. UBS Group restated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. Finally, Needham & Company LLC dropped their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $134.50.

TransMedics Group Trading Down 0.2%

Shares of NASDAQ:TMDX opened at $71.11 on Monday. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company’s fifty day simple moving average is $73.40 and its 200 day simple moving average is $107.39. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of 16.16 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.TransMedics Group’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.70 earnings per share. As a group, research analysts forecast that TransMedics Group will post 1.92 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in the company. D.A. Davidson & CO. increased its stake in TransMedics Group by 0.5% in the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after acquiring an additional 83 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares in the last quarter. HighPoint Advisor Group LLC increased its stake in shares of TransMedics Group by 3.1% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after purchasing an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. raised its holdings in shares of TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.